Proactive Investors - Run By Investors For Investors
Why invest in AC8?
AusCann Group Holdings Ltd: THE INVESTMENT CASE
INVESTMENT OVERVIEW

AusCann Group signs a medical cannabis deal with Columbia based Khiron Life Sciences

The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.
medical cannabis
INVESTMENT OVERVIEW: AC8 The Big Picture
Khiron is listed on the TSX Venture Exchange in Canada

AusCann Group Holdings Ltd’s (ASX:AC8) Chilean joint venture DayaCann has signed a memorandum of understanding (MoU) with Columbian medical cannabis company Khiron Life Sciences Corp (CVE:KHRN).

Khiron has its core operations in Colombia and aims to address the unmet medical needs in a market of over 620 million people in Latin America.

The MoU contemplates a method of collaboration through which new alternatives of medical cannabis are offered to patients in Chile.

To achieve this, the parties will engage in cultivation, manufacturing, pedagogical, scientific and other activities that present cannabinoid medicines as a viable medical option.

READ: AusCann Group commences trading in the US increasing global exposure

As part of the agreement, Khiron will provide funds to support the development of these activities.

Under the MoU, DayaCann will provide cultivation and manufacturing services to Khiron.

AusCann and Fundación Daya formed DayaCann in 2016 with the aim of becoming Latin America’s leading medicinal cannabis group.

It is worth noting that DayaCann is the only company in Chile to hold a medical cannabis production licence.

 

DayaCann has already completed two harvests at its 30-hectare facility yielding a total of over 1000 kilograms of dried cannabis flower.

A portion of this cannabis is being used by Chilean pharmaceutical manufacturing group, Knop Laboratories, to create medical cannabis products available to Chilean patients via a special access scheme.

READ: Auscann Group makes steady progress towards production of cannabinoid medicines

AusCann managing director Elaine Darby said: “We look forward to working with Khiron through our joint venture DayaCann.

“To be supplying them high quality cannabinoid medicines and working together on addressing the needs of the Latin American market.

“The MoU will not only expand DayaCann’s presence in Chile, but also give DayaCann wider access to the Latin American market.”

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

A cannabis facility
December 02 2018
The Vancouver-based medicinal cannabis grower’s Queensland facility will be the world's largest greenhouse cannabis operation, covering a 99-acre site
The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
October 31 2018
The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth
1540909388_Marijuana-stethoscope.jpg
October 31 2018
The firm wants to become the first publicly listed, globally focused, pure cannabis company

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use